**Androgenetic Alopecia (AGA)** is the most common type of progressive hair loss, affecting approximately 21% of men and 6% of women in China. Its core mechanism involves genetically susceptible hair follicles gradually miniaturizing under the action of dihydrotestosterone (DHT), leading to the transformation of terminal hairs into vellus hairs, receding hairlines, or thinning of the crown. Monotherapy often struggles to simultaneously intervene across multiple pathological pathways; thus, evidence-based combination treatment regimens are becoming the mainstream approach.
First, it must be clarified that any combination regimen should be based on a precise diagnosis. Physicians will use medical history, hair pull tests, trichoscopy (or dermoscopy), and, when necessary, hormone level testing to rule out other causes such as telogen effluvium, alopecia areata, and thyroid disorders. AGA is a chronic process; early intervention yields better results, but combination therapy cannot “reverse” already fully atrophied hair follicles—it can only slow progression and promote recovery of existing follicles.
**Evidence-Based Combinations of Core Medications**
Topical minoxidil (2% or 5%), FDA-approved for AGA, prolongs the anagen phase by opening potassium channels and promoting angiogenesis. Multiple randomized controlled trials have confirmed it increases hair density and diameter, but effects diminish within six months of discontinuation. Oral finasteride (1 mg/day, for men only) reduces scalp DHT by approximately 60% by inhibiting 5α-reductase, slowing disease progression; about 80% of users maintain stability. For female patients who are unwilling or unable to take oral medication, spironolactone (40–200 mg/day, with monitoring of serum potassium and blood pressure) acts as an antiandrogen to reduce DHT binding to receptors. Multiple studies show improvement in frontal hair loss, but the level of evidence is lower than that for finasteride.
Recommended classic combination: For mild-to-moderate male patients, “minoxidil 5% twice daily + finasteride 1 mg once daily” achieves an efficacy rate of over 80% at 18 months, significantly better than either agent alone. For female patients, a common regimen is “minoxidil 2%–5% twice daily + spironolactone (starting at 50 mg/day, gradually increased to a tolerated dose).” Note that spironolactone may cause polyuria, irregular menstruation, etc.
**Supporting Evidence for Physical Therapies**
Low-level laser therapy (LLLT, wavelength around 650 nm) increases ATP production in hair follicle cells and reduces inflammation; it has been FDA-cleared as an adjunctive device for AGA. A meta-analysis showed that LLLT combined with minoxidil improved hair density by approximately 15% compared with minoxidil alone. Microneedling (once weekly, needle length 0.5–1.5 mm) physically stimulates hair follicle stem cells while enhancing transdermal absorption of minoxidil. Randomized trials indicate that at 24 weeks, the microneedling + minoxidil group had approximately 40 more hairs/cm² than the minoxidil-alone group. The evidence level for autologous platelet-rich plasma (PRP) injections remains controversial; some small-sample studies show density improvement, but large controlled data are lacking, so it is not routinely recommended.
**Principles for Designing Combination Regimens**
Regimens should be individualized, taking into account sex, hair loss grade (Hamilton-Norwood or Ludwig), scalp tolerance, and economic costs. For example:
– Male H/N grade 2–3: Minoxidil + finasteride + LLLT (15 minutes daily); if improvement is suboptimal after 6 months, add microneedling.
– Female Ludwig grade I–II: Minoxidil + spironolactone + microneedling (every 2 weeks); contraception is necessary (spironolactone has teratogenic risk).
– All patients should undergo efficacy evaluation at 3–6 months using standardized photographic counts. Lack of response requires checking medication adherence and ruling out concurrent diseases.
**Important Limitations and Precautions**
– Minoxidil may cause an initial “shedding phase” (telogen hair loss), which is normal; finasteride leads to sexual dysfunction in approximately 1%–2% of men, with most recovering after discontinuation; spironolactone requires avoiding high-potassium foods.
– Combination therapy requires long-term adherence (typically 12 months to show effects), and efficacy diminishes after discontinuation.
– Hair transplantation (FUE/FUT) is an option for end-stage hair loss or when medications fail; pre- and post-operative medication should still be continued to maintain non-transplanted follicles.
– There is insufficient evidence to support the routine inclusion of vitamin D, zinc, biotin, or bio-shampoos as part of a combination regimen.
**Summary**
Based on current high-level evidence, the optimal treatment strategy for androgenetic alopecia involves combining medications (minoxidil + antiandrogen) with non-pharmacological modalities (LLLT or microneedling) to target DHT damage, follicular microcirculation, and mechanical activation across multiple dimensions. All regimens should be developed under the guidance of a dermatologist and dynamically adjusted based on response. Approach efficacy rationally and avoid blindly pursuing a “cure.”
For reference only; does not constitute medical advice. If you are experiencing hair loss, please consult a professional dermatologist for a standardized evaluation.